Related Experiment Video
Updated: Jan 7, 2026

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
Apolipoprotein M in Right Heart Failure
Background:
Right heart failure (RHF) leads to an elevation in central venous pressure and causes hepatic congestion. Apolipoprotein M (ApoM), a hepatocyte-derived lipocalin bound to high-density lipoprotein, transports sphingosine-1-phosphate (S1P), which maintains vascular integrity and modulates inflammation. Although low ApoM predicts adverse outcomes in heart failure (HF), its role in RHF is unclear. We sought to investigate the impact of RHF on circulating ApoM, its prognostic value in RHF mortality, and its functional role in the cardio-hepatic axis.
Methods:
Patients undergoing right heart catheterization were classified as normal, HF, or RHF. Serum ApoM and S1P were measured by ELISA. Survival was analyzed using Kaplan-Meier and Cox proportional hazards models. Meanwhile, ApoM Tg or WT mice were subjected to pulmonary artery banding (PAB) to induce right ventricular (RV) dysfunction or partial inferior vena cava ligation (pIVCL) to cause hepatic congestion. Cardiac and hepatic pathology were assessed by tissue imaging and molecular analyses.
Results:
ApoM levels were lowest in RHF patients and inversely correlated with inflammatory markers. Each 0.01 μM increase in ApoM was associated with a 6% lower risk of mortality. PAB induced RV dysfunction and reduced serum ApoM in wild-type mice, while ApoM Tg mice showed less severe RV remodeling and improved hepatic congestion. In contrast, ApoM Tg mice subjected to pIVCL showed no significant improvement in liver pathology.
Conclusion:
In patients with RHF and mice with RV dysfunction, circulating ApoM was reduced. Lower ApoM was independently associated with worse outcomes. Restoring ApoM expression primarily protects the heart and subsequently alleviates liver congestion, underscoring its distinct protective role in the heart-liver axis. Further investigation of the ApoM axis in RHF is warranted.
Disclosures:
Research reported in this publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number TL1TR002344. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Insights
Lower levels of Apolipoprotein M (ApoM) indicate worse outcomes in right heart failure (RHF). Restoring ApoM protects the heart and reduces liver congestion, highlighting its role in the heart-liver axis.
Area of Science:
- Cardiology
- Hepatology
- Biochemistry
Background:
- Right heart failure (RHF) causes hepatic congestion due to elevated central venous pressure.
- Apolipoprotein M (ApoM), a high-density lipoprotein-bound lipocalin, transports sphingosine-1-phosphate (S1P), crucial for vascular integrity and inflammation modulation.
- Low ApoM levels are linked to adverse outcomes in heart failure (HF), but its specific role in RHF remains unclear.
Purpose of the Study:
- To investigate the impact of RHF on circulating ApoM levels.
- To determine the prognostic value of ApoM in RHF-related mortality.
- To explore the functional role of ApoM in the cardio-hepatic axis.
Main Methods:
- Patients were categorized into normal, HF, or RHF groups based on right heart catheterization.
- Serum ApoM and S1P levels were quantified using ELISA.
- ApoM transgenic (Tg) and wild-type (WT) mice underwent pulmonary artery banding (PAB) or partial inferior vena cava ligation (pIVCL) to model RHF and hepatic congestion, respectively. Cardiac and hepatic tissues were analyzed.
Main Results:
- RHF patients exhibited the lowest ApoM levels, which inversely correlated with inflammatory markers.
- Each 0.01 μM increase in ApoM was associated with a 6% reduction in mortality risk.
- In mice, PAB reduced ApoM in WT mice; ApoM Tg mice showed attenuated RV remodeling and less hepatic congestion. However, ApoM Tg mice with pIVCL did not show improved liver pathology.
Conclusions:
- Circulating ApoM is reduced in both RHF patients and mice with RV dysfunction.
- Lower ApoM levels are an independent predictor of adverse outcomes in RHF.
- Restoring ApoM primarily benefits the heart, subsequently improving liver congestion, emphasizing its critical role in the heart-liver axis for RHF management.
Related Concept Videos
Cardiomyopathy V: Interprofessional Care
Mitral Regurgitation I: Introduction
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Heart Failure II: Pathophysiology
Heart Failure V: Medical Management

